These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39141925)

  • 1. Homologous Tumor Cell-Derived Biomimetic Nano-Trojan Horse Integrating Chemotherapy with Genetherapy for Boosting Triple-Negative Breast Cancer Therapy.
    Duan W; Shen Q; Ju L; Huang Z; Geng J; Wu Q; Yu C; Wei J
    ACS Appl Mater Interfaces; 2024 Aug; 16(34):45523-45536. PubMed ID: 39141925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy.
    Shao D; Zhang F; Chen F; Zheng X; Hu H; Yang C; Tu Z; Wang Z; Chang Z; Lu J; Li T; Zhang Y; Chen L; Leong KW; Dong WF
    Adv Mater; 2020 Dec; 32(50):e2004385. PubMed ID: 33164250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
    Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
    J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment.
    He Z; Zhang H; Li H; Wang Y; Qian J; Cai X; Sun L; Huang J
    Oxid Med Cell Longev; 2020; 2020():7152173. PubMed ID: 33488930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid-Activated TAT Peptide-Modified Biomimetic Boron Nitride Nanoparticles for Enhanced Targeted Codelivery of Doxorubicin and Indocyanine Green: A Synergistic Cancer Photothermal and Chemotherapeutic Approach.
    Li H; Fan Y; Shen Y; Xu H; Zhang H; Chen F; Feng S
    ACS Appl Mater Interfaces; 2024 May; 16(19):25101-25112. PubMed ID: 38691046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
    Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
    J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
    Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
    Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer.
    Zhang T; Bai L; You R; Yang M; Chen Q; Cheng Y; Qian Z; Wang Y; Liu Y
    J Mater Chem B; 2024 Jun; 12(22):5465-5478. PubMed ID: 38742364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
    Wang S; Zhang J; Wang Y; Chen M
    Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
    Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
    Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
    Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
    Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Dual-Action Chemo-Radio-Labeled Nanocarriers with High Efficacy against Triple-Negative Breast Cancer.
    Ilyas S; E M Sahnoun S; Szymura A; Pes J; Habib S; Florea A; Schäfer L; Buhl EM; Morgenroth A; Habib P; Mottaghy FM; Mathur S
    ACS Appl Mater Interfaces; 2023 Oct; 15(42):48963-48977. PubMed ID: 37831583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.
    Ahir M; Upadhyay P; Ghosh A; Sarker S; Bhattacharya S; Gupta P; Ghosh S; Chattopadhyay S; Adhikary A
    Biomater Sci; 2020 May; 8(10):2939-2954. PubMed ID: 32319481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy, Antiangiogenesis and Immunotherapy.
    Lan J; Chen L; Li Z; Liu L; Zeng R; He Y; Shen Y; Zhang T; Ding Y
    Adv Healthc Mater; 2024 Oct; 13(26):e2400046. PubMed ID: 38767575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of Pyruvate Kinase M2
    Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
    ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Unique Approach: Biomimetic Graphdiyne-Based Nanoplatform to Treat Prostate Cancer by Combining Cuproptosis and Enhanced Chemodynamic Therapy.
    Xie W; Zhang Y; Xu Q; Zhong G; Lin J; He H; Du Q; Tan H; Chen M; Wu Z; Deng Y; Han Z; Lu J; Ye J; Zou F; Zhuo Y; Zhong W
    Int J Nanomedicine; 2024; 19():3957-3972. PubMed ID: 38711614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer.
    Jiang Q; Liu L; Li Q; Cao Y; Chen D; Du Q; Yang X; Huang D; Pei R; Chen X; Huang G
    J Nanobiotechnology; 2021 Mar; 19(1):64. PubMed ID: 33653352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.